Background: The comparative effectiveness of rheumatoid arthritis therapies is uncertain.
Purpose: To compare the benefits and harms of disease-modifying antirheumatic drugs …

Background One of the key elements of comparative treatment effectiveness research is
head-to-head trials. We herein describe the control arms and the treatment received by …

Objective. The Canadian Rheumatology Association (CRA) has developed
recommendations for the pharmacological management of rheumatoid arthritis (RA) with …

Objective. The Canadian Rheumatology Association (CRA) has developed
recommendations for the pharmacological management of rheumatoid arthritis (RA) with …

In the last 25 years, there has been a substantial shift in the therapeutic algorithm for
rheumatoid arthritis (RA) toward early intensive therapy. The shift has been driven by the …

Guidelines and recommendations developed and/or endorsed by the American College of
Rheumatology (ACR) are intended to provide guidance for particular patterns of practice …

Study Objective. To compare the efficacy of biologic disease‐modifying antirheumatic drugs
(DMARDs) versus placebo with or without methotrexate, in treating rheumatoid arthritis …

The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

Objective Treatment guidelines for rheumatoid arthritis (RA) now recommend early,
aggressive, and persistent use of disease‐modifying antirheumatic drugs (DMARDs) to …

Introduction. Combinations of disease-modifying anti-rheumatic drugs (DMARDs) are
increasingly used to treat rheumatoid arthritis (RA). Early trials showed their toxicity while …